The Lovaas Legacy

The modern ABA dosage standard traces to a single study. In 1987, Ole Ivar Lovaas published the seminal paper demonstrating that approximately 47 percent of children who received 40 hours per week of early intensive behavioral intervention (EIBI) achieved normal intellectual and educational functioning, compared to only 2 percent of children in a control group receiving 10 hours per week. The study was a landmark moment for the field: it provided the empirical foundation for the argument that ABA works, and it established the dosage range — 30 to 40 hours per week — that would become the standard recommendation for young children with autism for the next three decades.

The Lovaas study’s influence was extraordinary. It shaped the ABA practice guidelines that most BCBAs follow today. The Council of Autism Service Providers (CASP) and other professional bodies have recommended comprehensive ABA treatment of 25 to 40 hours per week for young children with significant skill deficits. These recommendations, in turn, shaped the insurance authorization frameworks that determine how many hours payers will approve. The result was a self-reinforcing system: researchers published on intensive ABA, guidelines recommended intensive ABA, payers authorized intensive ABA, and providers built business models around billing 25 to 40 hours per week per client.

The Lovaas study has been critiqued on methodological grounds since its publication. Critics have noted the small sample size (19 children in the intensive group), the lack of random assignment, the use of aversive procedures that would be considered unethical today, and the difficulty of defining and measuring the outcome variable of normal functioning. A 2005 follow-up study found that 48 percent of children receiving intensive ABA integrated into regular education classrooms by age seven — broadly consistent with the original findings but still based on a relatively narrow definition of success.

But the methodological critiques are not what is threatening the 40-hour dogma. What is threatening it is a growing body of real-world data showing that the dose-response relationship in ABA is far more complex than the linear model that the Lovaas study implied. More hours may not equal better outcomes — and the research published in 2024, 2025, and 2026 is making that case with increasingly compelling data.

The 2024–2026 Research Wave

A January 2026 study published in the Journal of Autism and Developmental Disorders examined real-world data from 725 autistic children receiving community-based ABA. Using longitudinal multilevel modeling, the researchers examined the relationship between average hours of ABA per month and change on multiple outcome measures: adaptive behavior (Vineland Adaptive Behavior Scales), goal attainment, and dangerous behavior. The study’s findings directly challenged the more-is-better assumption.

The study found that treatment intensity explained a meaningful portion of variance in goal attainment but showed no significant relationship between hours per month and improvement in adaptive behavior or reduction in dangerous behavior. The findings suggest that the overall quantity of therapy may be a poor predictor of some outcomes, and that factors other than dosage — such as the quality of supervision, the match between the treatment plan and the child’s needs, and caregiver involvement — may account for a larger share of treatment response.

A separate study published in PMC examined data from children receiving ABA services in a community setting and stratified outcomes by dosage level. Children receiving fewer than 40 hours of ABA services per month demonstrated statistically significant improvement in the Vineland Adaptive Behavior Composite Standard Score as well as in all domain-specific scores. The improvements in the lower-hour group were also clinically significant in the Composite, Communication, and Socialization domains. However, improvements for children receiving 40 or more hours per month were not statistically significant.

The authors noted that the absence of significant differences between the higher and lower dosage groups was reinforced by the finding that there was no significant association between hours of service and Vineland standard score improvements. The Pearson correlation coefficients never exceeded 0.117. The lack of significant differences and correlations supports the notion that improvements in Vineland scores were independent of the treatment dose.

A National Academies of Medicine report found that treatment intensity was associated with improved outcomes, but the dose-response relationship was unclear, especially at higher doses and later in the treatment course. More recent studies demonstrated that treatment intensity and duration only accounted for about 60 percent of the variance in treatment response, meaning at least 40 percent of variation was attributable to factors other than how many hours the child received.

A 2024 study published in JABA developed and validated the Patient Outcome Planning Calculator (POP-C), a tool designed to help BCBAs determine medically necessary treatment dosage. The tool’s development was motivated by the observation that there is currently no standard method for making dosage determinations, and that BCBAs must rely on their own clinical judgment — judgment that may be underdeveloped in newly certified practitioners. The POP-C represents a formal attempt to move dosage decisions from tradition and intuition toward data-driven individualization.

As an industry, we’ve dug ourselves into this hole. And the payers themselves have no empathy for the ABA providers who have been billing them 40 hours a week and $75,000 a year for the same kid for five years without any quality scores. — Jeff Beck, CEO, AnswersNow

The Payer Pressure

The dosage debate is not merely academic. Payers are applying economic pressure that is forcing providers to justify treatment intensity with data rather than tradition. The OIG audits found that some providers billed 30 to 40 therapy hours per week for nearly every child, despite expert guidance that such intensive schedules are rarely needed. Benesch’s analysis identified this uniform high-intensity pattern as a fraud red flag because it suggests that business incentives rather than clinical judgment are driving treatment recommendations.

RethinkFutures’ clinical decision support platform provides evidence-based ABA intensity recommendations to health plans, ensuring consistent application of benefits so that the appropriate amount of services are being authorized. For payers, the question is no longer whether ABA works — it is whether 40 hours per week is necessary for every child, or whether lower-intensity models can produce comparable outcomes at lower cost.

Jeff Beck of AnswersNow has been among the most vocal industry voices on dosage reform. At the Autism Innovation Exchange webinar in February 2026, Beck said: as an industry, we’ve dug ourselves into this hole. And the payers themselves have no empathy for the ABA providers who have been billing them 40 hours a week and $75,000 a year for the same kid for five years without any quality scores. AnswersNow’s model — all-BCBA, telehealth-delivered, parent-mediated — is built explicitly around lower hours and higher clinical intensity per session.

Indiana’s FSSA imposed a 4,000-hour lifetime cap on ABA services, the most aggressive utilization control ever imposed by a state Medicaid program. While the cap was driven by budget concerns rather than clinical evidence, it reflects the growing willingness of payers to challenge the assumption that more hours are always better. The cap effectively forces providers to demonstrate progress and plan for discharge rather than maintaining children on high-hour treatment plans indefinitely.

Catalight, one of the largest behavioral health nonprofits in the nation, has explicitly adopted what it calls a quality over quantity approach. The organization’s chief health officer, Tracy Gayeski, stated that too often, services are driven by quantity rather than quality. The system can be difficult to navigate, slow to diagnose and treat, and costly with limited evidence of effectiveness. Catalight’s training programs emphasize parent-mediated and telehealth-enabled care models that have demonstrated effectiveness with fewer direct therapy hours.

The Clinical-Economic Tension

For BCBAs, the dosage debate creates a genuine ethical tension. The BACB Ethics Code requires behavior analysts to recommend treatment that is in the client’s best interest based on the available evidence. If the evidence increasingly shows that lower-intensity treatment can produce comparable outcomes for many clients, then recommending 40 hours per week for every child may not be ethically defensible. But the business model of most ABA practices — and the compensation structure of most BCBAs — is built around maximizing billable hours.

A BCBA who recommends reducing a client’s hours from 30 to 15 per week based on clinical data is making the ethically correct decision if the evidence supports it. But that decision reduces the practice’s revenue by 50 percent for that client. In a PE-backed practice with revenue targets, the BCBA may face pressure — explicit or implicit — to maintain higher hours. In an independent practice, the BCBA-owner faces the same tension between clinical judgment and business viability.

The field is beginning to address this tension through dosage individualization frameworks. The POP-C tool provides a structured method for determining treatment intensity based on individual patient factors rather than a one-size-fits-all recommendation. CASP’s updated guidelines emphasize individualized treatment planning that considers the child’s specific needs, family circumstances, and response to treatment. The movement is toward prescribing the minimum effective dose — the lowest intensity of treatment that produces meaningful clinical progress — rather than defaulting to the maximum hours that payers will authorize.

Modern ABA practitioners increasingly describe their goal as working themselves out of a job. The purpose of ABA is to help a child work towards independence and successful functioning in their daily lives, not to attend ABA for the rest of their life. This perspective represents a philosophical shift from the Lovaas-era model of intensive, long-duration treatment toward a model of targeted, efficient intervention designed to produce independence as quickly as possible.

The dosage reform has implications for every stakeholder in ABA. For providers, it means building business models that can sustain profitability at lower average hours per client. For payers, it means developing authorization frameworks that reward efficiency rather than volume. For BCBAs, it means developing clinical judgment skills that go beyond defaulting to the highest authorized hours. For families, it means treatment plans that respect their time, their child’s tolerance, and the growing evidence that quality matters more than quantity.

The 40-hour question is not settled. Young children with significant skill deficits may still benefit from comprehensive treatment in the 25-to-40-hour range. But the assumption that 40 hours is the default for every child — the assumption that drove a $287 million Medicaid benefit in Colorado, a $135 million program in Indiana, and thousands of treatment plans across the country — is no longer supported by the weight of the evidence. The dosage dogma is dying. What replaces it will define the next era of ABA clinical practice.

AT A GLANCE

SOURCES & REFERENCES